ALPINE
A Phase II, single-arm trial of Atezolizumab/Platinum/Etoposide for the treatment of advanced large-cell neuroendocrine cancer of the lung
II
interventionell
National
Atezolizumab (IMP) + Platin/Etoposid (standard-of-care)
Status: Rekrutierung beendet
Zeitraum
2021
2025
Patienten
67
67
12.02.2025
Klinische Settings
IIIC, IV, IVA, IVB, IVC
1st line, front line
palliativ
Identifier
AIO-TRK-0322
TUD-ALPINE-077
2020-002683-31
Kontakt
Leitung
Prof. Dr. med. Martin Wermke
Ansprechpartner*in
Dr. med. Felix Carl Saalfeld
E-Mail alpine@ukdd.de